Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Is Mammography for Breast Cancer Screening Cost-Effective in Both Western and Asian Countries?: Results of a Systematic Review

  • Yoo, Ki-Bong (Department of Public Health, Graduate School, Yonsei University) ;
  • Kwon, Jeoung A (Department of Public Health, Graduate School, Yonsei University) ;
  • Cho, Eun (College of Pharmacy, Sookmyung Women's University) ;
  • Kang, Moon Hae (Department of Public Health, Graduate School, Yonsei University) ;
  • Nam, Jung-Mo (Department of Preventive Medicine, Yonsei University College of Medicine) ;
  • Choi, Kui Son (National Cancer Control Institute, National Cancer Center) ;
  • Kim, Eun Kyung (Department of Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine) ;
  • Choi, Yun Jeong (School of Economics, Yonsei University) ;
  • Park, Eun-Cheol (Institute of Health Services Research)
  • Published : 2013.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Mammography is considered the gold standard of breast cancer mass screening and many countries have implemented this as an established breast cancer screening strategy. However, although the incidence of breast cancer and racial characteristics are different between Western and Asian countries, many Asian countries adopted mammography for mass screening. Therefore, the objective of this research was to determine whether mammography mass screening is cost-effective for both Western and Asian countries. Materials and Methods: A systematic review was performed of 17 national mammography cost-effectiveness data sets. Per capita gross domestic product (GDP), breast cancer incidence rate, and the most optimal cost-effectiveness results [cost per life year saved (LYS)] of a mammography screening strategy for each data set were extracted. The CE/per capita GDP ratio is used to compare the cost-effectiveness of mammography by countries. Non-parametric regression was used to find a cut-off point which indicated the breast cancer incidence rate boundary line determining whether mammography screening is cost-effective or not. Results: We found that the cost-effective cut-off point of breast cancer incidence rate was 45.04; it exactly divided countries into Western and Asian countries (p<0.0014). Conclusions: Mammography screening is cost-effective in most of Western countries, but not in Asian countries. The reason for this result may be the issues of incidence rate or racial characteristics, such as dense breast tissue. The results indicate that mammography screening should be adopted prudently in Asian countries and other countries with low incidence rates.

Keywords

References

  1. Carles M, Vilaprinyo E, Cots F, et al (2011). Cost-effectiveness of early detection of breast cancer in Catalonia (Spain). BMC Cancer, 11, 192. https://doi.org/10.1186/1471-2407-11-192
  2. Carney PA, Miglioretti DL, Yankaskas BC, et al (2003). Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med, 138, 168-75. https://doi.org/10.7326/0003-4819-138-3-200302040-00008
  3. de Gelder R, Bulliard J-L, de Wolf C, et al (2009). Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. Eur J Cancer, 45, 127-38. https://doi.org/10.1016/j.ejca.2008.09.015
  4. de Koning HJ, Fracheboud J, Boer R, et al (1995). Nation-wide breast cancer screening in The Netherlands: support for breast-cancer mortality reduction. National Evaluation Team for Breast Cancer Screening (NETB). Int J Cancer, 60, 777-80. https://doi.org/10.1002/ijc.2910600608
  5. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al (1991). Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer, 49, 531-7. https://doi.org/10.1002/ijc.2910490410
  6. El-Bastawissi AY, White E, Mandelson MT, Taplin S (2001). Variation in mammographic breast density by race. Ann Epidemiol, 11, 257-63. https://doi.org/10.1016/S1047-2797(00)00225-8
  7. Evans DG, Warwick J, Astley SM, et al (2012). Assessing individual breast cancer risk within the UK national health service breast screening program: a new paradigm for cancer prevention. Cancer Prev Res (Phila), 5, 943-51. https://doi.org/10.1158/1940-6207.CAPR-11-0458
  8. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  9. Fracheboud J, de Koning HJ, Beemsterboer PM, et al (1998). Nation-wide breast cancer screening in The Netherlands: results of initial and subsequent screening 1990-1995. National Evaluation Team for Breast Cancer Screening. Int J Cancer, 75, 694-8. https://doi.org/10.1002/(SICI)1097-0215(19980302)75:5<694::AID-IJC6>3.0.CO;2-U
  10. Garuz R, Forcen T, Cabases J, et al (1997). Economic evaluation of a mammography-based breast cancer screening programme in Spain. Eur J Public Health, 7, 68-76. https://doi.org/10.1093/eurpub/7.1.68
  11. Graham-Rowe D (2012). Risk analysis: a dense issue. Nature, 485, 60-1. https://doi.org/10.1038/485S60a
  12. Green M, Raina V (2008). Epidemiology, screening and diagnosis of breast cancer in the Asia-Pacific region: Current perspectives and important considerations. Asia Pac J Clin Oncol, 4, 5-13. https://doi.org/10.1111/j.1743-7563.2008.00191.x
  13. Hardle W (1990). Applied nonparametric regression. Cambridge University Press, UK.
  14. Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S (2012). Breast cancer incidence trends in Norway--explained by hormone therapy or mammographic screening? Int J Cancer, 130, 2930-8. https://doi.org/10.1002/ijc.26280
  15. Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al (2005). The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer, 6, 391-401. https://doi.org/10.3816/CBC.2005.n.043
  16. Huang CS, Chang KJ, Shen CY (2001). Breast cancer screening in Taiwan and China. Breast Dis, 13, 41-8.
  17. IARC (2011). International Agency for Research on Cancer:CI5plus. http://ci5.iarc.fr/CI5plus/ci5plus.htm.
  18. Kang MH, Park EC, Choi KS, et al (2013). The national cancer screening program for breast cancer in the republic of korea: is it cost-effective? Asian Pac J Cancer Prev, 14, 2059-65. https://doi.org/10.7314/APJCP.2013.14.3.2059
  19. Kikuchi M, Tsunoda H, Koyama T, et al (2012). Opportunistic breast cancer screening by mammography in Japan for women in their 40s at our preventive medical center: harm or benefit? Breast Cancer, [Epub ahead of print].
  20. Kim Y, Jun JK, Choi KS, et al (2011). Overview of the National Cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev, 12, 725-30.
  21. Knox EG (1988). Evaluation of a proposed breast cancer screening regimen. BMJ, 297, 650-4. https://doi.org/10.1136/bmj.297.6649.650
  22. Leivo T, Sintonen H, Tuominen R, et al (1999). The cost-effectiveness of nationwide breast carcinoma screening in Finland, 1987-1992. Cancer, 86, 638-46. https://doi.org/10.1002/(SICI)1097-0142(19990815)86:4<638::AID-CNCR12>3.0.CO;2-H
  23. Leong SP, Shen ZZ, Liu TJ, et al (2010). Is breast cancer the same disease in Asian and Western countries? World J Surg, 34, 2308-24. https://doi.org/10.1007/s00268-010-0683-1
  24. Leung TK, Huang PJ, Chen CS, et al (2010). Is breast MRI screening more effective than digital mammography in Asian women? J Exp Clin Med, 2, 245-50. https://doi.org/10.1016/S1878-3317(10)60038-1
  25. Lindfors KK, Rosenquist CJ (1995). The cost-effectiveness of mammographic screening strategies. JAMA, 274, 881-4. https://doi.org/10.1001/jama.1995.03530110043033
  26. Lynge E, Braaten T, Njor SH, et al (2011). Mammography activity in Norway 1983 to 2008. Acta Oncol, 50, 1062-7. https://doi.org/10.3109/0284186X.2011.599339
  27. Ma GX, Yin L, Gao W, et al (2012). Workplace-based breast cancer screening intervention in china. Cancer Epidemiol Biomarkers Prev, 21, 358-67. https://doi.org/10.1158/1055-9965.EPI-11-0915
  28. Mandelblatt JS, Cronin KA, Bailey S, et al (2009). Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med, 151, 738-47. https://doi.org/10.7326/0003-4819-151-10-200911170-00010
  29. Maurice A, Evans DG, Affen J, et al (2012). Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit. Int J Cancer, 131, 417-25. https://doi.org/10.1002/ijc.26394
  30. Norum J (1999). Breast cancer screening by mammography in Norway. Is it cost-effective? Ann Oncol, 10, 197-203.
  31. Ofman JJ, Sullivan SD, Neumann PJ, et al (2003). Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm, 9, 53-61.
  32. Ohuchi N, Suzuki A, Sakurai Y, et al (2009). Current status and problems of breast cancer screening. JMAJ, 52, 45-9.
  33. Okonkwo QL, Draisma G, der Kinderen A, et al (2008). Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst, 100, 1290-300. https://doi.org/10.1093/jnci/djn292
  34. Okubo I, Glick H, Frumkin H, Eisenberg JM (1991). Cost-effectiveness analysis of mass screening for breast cancer in Japan. Cancer, 67, 2021-9. https://doi.org/10.1002/1097-0142(19910415)67:8<2021::AID-CNCR2820670802>3.0.CO;2-L
  35. Olsen AH, Lynge E, Njor SH, et al (2013). Breast cancer mortality in Norway after the introduction of mammography screening. Int J Cancer, 132, 208-14. https://doi.org/10.1002/ijc.27609
  36. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  37. Peterson LE, Goodman C, Karnes EK, et al (2009). Assessment of the quality of cost analysis literature in physical therapy. Phys Ther, 89, 733-55. https://doi.org/10.2522/ptj.20080326
  38. Rosenquist CJ, Lindfors KK (1998). Screening mammography beginning at age 40 years: a reappraisal of cost-effectiveness. Cancer, 82, 2235-40. https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2235::AID-CNCR19>3.0.CO;2-V
  39. Schousboe JT, Kerlikowske K, Loh A, Cummings SR (2011). Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med, 155, 10-20. https://doi.org/10.7326/0003-4819-155-1-201107050-00003
  40. Shapiro S, Coleman EA, Broeders M, et al (1998). Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European network of pilot projects for breast cancer screening. Int J Epidemiol, 27, 735-42. https://doi.org/10.1093/ije/27.5.735
  41. Stout NK, Rosenberg MA, Trentham-Dietz A, et al (2006). Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst, 98, 774-82. https://doi.org/10.1093/jnci/djj210
  42. The World Bank (2013). GDP per capita. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
  43. Tonelli M, Gorber SC, Joffres M, et al (2011). Recommendations on screening for breast cancer in average-risk women aged 40-74 years. Cmaj, 183, 1991-2001. https://doi.org/10.1503/cmaj.110334
  44. USPSTF (2009). Screening for breast cancer: US preventive services task force recommendation statement. Ann Intern Med, 151, 716-26. https://doi.org/10.7326/0003-4819-151-10-200911170-00008
  45. Van der Mass PJ, De Koning HJ, Van Ineveld BM, et al (1989). The cost-effectiveness of breast cancer screening. Int J Cancer, 43, 1055-60. https://doi.org/10.1002/ijc.2910430617
  46. White E, Lee CY, Kristal AR (1990). Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst, 82, 1546-52. https://doi.org/10.1093/jnci/82.19.1546
  47. WHO. (2001). Macroeconomics and Health: Investing in Health for Economic Development: Report of the Commission on Macroeceonomics and Health. Chaired by Jeffrey D. Sachs, Presented to Gro Harlem Brundtland, Director-General of the World Health Organization, Geneva, Switzerland.
  48. Wong IOL, Kuntz KM, Cowling BJ, et al (2010). Cost-effectiveness analysis of mammography screening in Hong Kong Chinese using state-transition Markov modelling. Hong Kong Med J, 16, 38-41.
  49. Woo PPS, Kim JJ, Leung GM (2007). What is the most cost-effective population-based cancer screening program for Chinese women? J Clin Oncol, 25, 617-24. https://doi.org/10.1200/JCO.2006.06.0210
  50. Yip CH, Smith RA, Anderson BO, et al (2008). Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer, 113, 2244-56. https://doi.org/10.1002/cncr.23842
  51. Zheng S, Bai JQ, Li J, et al (2012). The pathologic characteristics of breast cancer in China and its shift during 1999-2008: A national-wide multicenter cross-sectional image over 10 years. Int J Cancer, 131, 2622-31. https://doi.org/10.1002/ijc.27513

Cited by

  1. Comparison of Male and Female Breast Cancer Incidence and Mortality Trends in Central Serbia vol.14, pp.10, 2013, https://doi.org/10.7314/APJCP.2013.14.10.5681
  2. Validation of Electrical Impedance Tomography Qualitative and Quantitative Values and Comparison of the Numeric Pain Distress Score against Mammography vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5759
  3. Influence of Service Characteristics on High Priority Performance Indicators and Standards in the BreastScreen Australia Program vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5901
  4. Facilitator Psychological Constructs for Mammography Screening among Iranian Women vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7309
  5. Can Ultrasound be Used to Differentiate Tubular Adenomas of Breast from Fibroadenomas or Carcinoma? vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1269
  6. Epidemiological Patterns of Cancer Incidence in Southern China: Based on 6 Population-based Cancer Registries vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1471
  7. Female Breast Cancer Incidence and Mortality in Mexico, 2000-2010 vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1477
  8. Correlation Study of Knowledge and Behavior Regarding Breast Care among Female Undergraduate Students in China vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10943
  9. Breast Cancer Diagnosis by Mammography in Kazakhstan - Staging Results of Breast Cancer with Double Reading vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.31
  10. Mammography screening in less developed countries vol.4, pp.1, 2015, https://doi.org/10.1186/s40064-015-1394-8
  11. Cost-Effectiveness Analysis of Breast Cancer Screening in Rural Iran vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.609
  12. Societal costs and effects of implementing population-based mammography screening in Greenland vol.76, pp.1, 2017, https://doi.org/10.1080/22423982.2017.1373580
  13. The health economics of cancer screening in Germany: Which population-based interventions are cost-effective? vol.61, pp.12, 2018, https://doi.org/10.1007/s00103-018-2839-3
  14. BRCA1/2-negative, high-risk breast cancers (BRCAX) for Asian women: genetic susceptibility loci and their potential impacts vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-31859-8
  15. A cross sectional study on the motivators for Asian women to attend opportunistic mammography screening in a private hospital in Malaysia: the MyMammo study vol.15, pp.1, 2015, https://doi.org/10.1186/s12889-015-1892-1